⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TRVI News
Trevi Therapeutics, Inc. Common Stock
Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)
prnewswire.com
TRVI
Trevi Therapeutics Provides Strategic Updates Ahead of Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference
prnewswire.com
TRVI
Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer
prnewswire.com
TRVI
Trevi Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
prnewswire.com
TRVI
Trevi Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 13, 2025
prnewswire.com
TRVI
Trevi Therapeutics to Participate in Stifel 2025 Healthcare Conference
prnewswire.com
TRVI
Trevi Therapeutics Announces Oral Presentation and Abstracts at CHEST 2025 Annual Meeting
prnewswire.com
TRVI
Trevi Therapeutics Announces Two Posters from the Phase 2a RIVER Trial Data Will be Featured at the European Respiratory Society (ERS) Congress 2025
prnewswire.com
TRVI